There is a moment in stroke recovery that most patients and families recognise. In the first weeks, progress is visible and almost daily — a hand that starts to grip, a word that returns, a step taken without support. Then the pace slows. The improvements come further apart, then seem to stop. Neurologists call this the plateau. For many people, it arrives somewhere between three and six months after the stroke, and from that point, conventional rehabilitation has relatively little to offer in terms of further functional gains.

It is precisely here — when the standard system runs out of road — that patients begin asking whether something else exists. Stem cell therapy is increasingly part of that conversation. This article explains what the science actually shows, where it is credible, and what someone considering treatment in 2026 should realistically expect.

What happens to the brain after a stroke?

Ischaemic stroke — which accounts for around 85% of all strokes — occurs when a blocked blood vessel cuts off oxygen to part of the brain. Cells at the core of the affected area die within minutes. Around this core is a zone called the penumbra: tissue that is injured but not yet dead, and that may survive if blood flow is restored quickly enough. Emergency treatments like clot-dissolving drugs and mechanical clot removal target this window.

After the acute phase, a secondary wave of damage continues through inflammation, swelling, and cell death. Over weeks, the damaged area is gradually replaced by scar tissue, and the surrounding brain undergoes a process of reorganisation — existing circuits adapting to compensate for lost function. This reorganisation is the biological basis for the recovery that rehabilitation supports.

The fundamental limitation is that the adult brain has very limited capacity to generate new neurons. The cells lost to stroke are largely not replaced. Conventional rehabilitation works by strengthening surviving circuits; it cannot rebuild what was destroyed.

This is the gap that stem cell therapy is trying to address.

How do UC-MSCs work in stroke recovery?

Mesenchymal stem cells from umbilical cord tissue — known as UC-MSCs — are not believed to work primarily by replacing lost neurons. The adult brain is not an environment where transplanted cells reliably become new neurons. What the research supports, more consistently, is a set of indirect effects that create better conditions for the brain’s own recovery.

When UC-MSCs are introduced into the body, they tend to migrate toward areas of inflammation and injury. Once there, they release a range of molecules that influence the surrounding tissue:

Reducing brain inflammation.

The inflammatory response that follows stroke can become chronically damaging. UC-MSCs appear to shift this response in a less destructive direction, which may limit secondary injury to tissue that is at risk but not yet lost.

Supporting new blood vessel growth

UC-MSCs release signals — particularly a protein called VEGF — that encourage the formation of new small blood vessels around the damaged area. Better circulation supports tissue survival and extends the window for recovery.

Releasing growth factors

UC-MSCs secrete molecules called BDNF and NGF, which support the survival of existing neurons and encourage the growth of new connections between them. These are the same growth factors that the brain naturally uses during recovery — UC-MSCs appear to boost their availability.

Modulating scar formation

The brain forms a glial scar after stroke, which limits further damage but also restricts regrowth of nerve fibres. There is evidence that MSCs may influence how this scar forms, potentially leaving more pathways available for recovery.

Taken together, these mechanisms suggest that UC-MSCs work by making the brain’s environment more favourable for its own repair processes — not by replacing what was lost, but by supporting what remains.

What does the current evidence show?

Research into stem cell therapy for stroke has grown substantially over the past decade. Multiple human studies have been published, and the overall picture that emerges from this body of work is encouraging, though it is important to understand what has been established and what has not.

Is it safe?

Safety is the clearest finding in the current evidence. Studies using intravenous UC-MSC administration have consistently reported acceptable safety profiles. Serious adverse events directly linked to the cells themselves have been uncommon, no tumour formation has been reported in human studies to date, and the cells do not appear to trigger significant immune reactions — an advantage of UC-MSCs specifically, which have low immunogenicity meaning the body is unlikely to reject them.

Does it work?

Research has reported improvements in functional outcomes in stroke patients receiving MSC therapy — including improvements in movement, independence in daily activities, and neurological scores — compared to patients who did not receive treatment. These findings are meaningful and provide genuine clinical rationale for the approach.

The honest context is that the evidence base, while growing, is still developing. The studies conducted so far have used different cell types, doses, and delivery methods, which makes direct comparison difficult. The scientific community is still working to identify which patients benefit most, what the optimal protocol looks like, and how durable the gains are over time.

This does not mean the therapy does not work. It means that the level of evidence has not yet reached the threshold required for stem cell therapy to appear in standard stroke guidelines — a threshold that takes years and large multicentre studies to cross. For patients who have reached the recovery plateau and have been informed honestly about both the evidence and its limits, the existing research provides reasonable scientific grounds to consider it as an option.

Does the timing of treatment matter?

Yes, and it is one of the clearest patterns in the research.

The majority of studies showing functional improvements have treated patients in the subacute phase — roughly one week to three months after the stroke. This window makes biological sense. Brain inflammation is still active, which may support the MSCs’ homing and signalling activity. Neuroplastic reorganisation is also at its most dynamic during this period, meaning the brain is most receptive to factors that support recovery.

Treatment in the chronic phase — more than six months after stroke — is not impossible, and studies have been conducted in this population. But the evidence for significant functional gains in long-standing stroke is weaker. The brain’s plasticity has diminished, the inflammatory environment that helps guide MSCs to injury sites has largely resolved, and the opportunity to limit secondary damage has passed.

This does not mean chronic stroke patients cannot benefit, but it is important to set realistic expectations. Anyone presenting years after their stroke hoping for dramatic reversal of deficits is unlikely to find that in the current evidence.

Which delivery route is used?

Several approaches have been studied, including direct injection into the brain, injection into the artery supplying the affected area, and intravenous infusion through a drip.

Intravenous infusion is the most widely used approach in clinical settings. It is safe, well-tolerated, and does not require surgery. A proportion of the cells are captured by the lungs before reaching the brain — this is a known limitation — but the evidence suggests that systemic anti-inflammatory and growth factor effects still contribute to benefit even when direct brain delivery is limited.

Most clinic-based protocols in 2025 use IV infusion, sometimes with additional routes in more intensive protocols. For most patients, intravenous administration represents the most reasonable balance of safety and practicable efficacy.

What are realistic expectations for patients?

• Safety from qualified providers using GMP-certified cells — meaning cells manufactured under strict pharmaceutical-grade quality controls — appears acceptable based on what has been published.
• Functional benefit varies substantially by patient. The research suggests better outcomes are associated with treating patients earlier after stroke, in those with milder deficits, and in younger patients. Patients with severe deficits, large infarcts, or stroke occurring many years ago are less likely to see dramatic recovery.
• Stem cell therapy is not a replacement for rehabilitation. The evidence suggests that MSCs create a more favourable biological environment for recovery — which means the gains are most likely to be realised when paired with active physiotherapy, speech therapy, and occupational therapy. Treatment without concurrent rehabilitation is likely to underperform.
• Results take time. Improvements following MSC therapy — when they occur — typically become apparent over weeks to months, not days. This is consistent with the biological mechanisms involved, which support gradual neural adaptation rather than immediate restoration.

The scientific case for UC-MSC therapy in stroke is biologically coherent and supported by a meaningful body of human research. Safety data is reassuring. Functional improvement signals are real. The limitations are those of an emerging field that has not yet accumulated the volume of large, long-term trials required for guideline inclusion — not evidence of inefficacy.

For stroke patients who have reached the recovery plateau, who have been informed honestly about what the evidence shows and what it does not yet definitively prove, and who are working with physicians who integrate this approach with conventional rehabilitation, UC-MSC therapy represents a rational option to consider. It is not a cure. It is not guaranteed. But it rests on credible science, and that science is still developing.

Frequently asked questions

Can stem cells repair the brain after a stroke?

Stem cells do not repair the brain by replacing lost neurons. What UC-MSCs appear to do is create better conditions for the brain’s own recovery: reducing inflammation, supporting new blood vessel growth, and releasing growth factors that encourage the formation of new neural connections. Recovery happens through the brain’s existing capacity to adapt, which the cells appear to support.

How soon after stroke should stem cell treatment be given?

Research shows the strongest results in the subacute phase — roughly one week to three months after stroke. This is when the brain is most plastic and most receptive to regenerative support. Treatment in the chronic phase is possible but generally shows more modest results. Timing should be discussed with a physician who knows the details of your case.

Is stem cell therapy for stroke safe?

Published human research using intravenous MSC administration has consistently reported acceptable safety profiles, with no significant increase in serious adverse events and no tumour formation reported. Cells should be GMP-certified and treatment should be supervised by a qualified physician. Safety data from unregulated providers cannot be assumed to match what has been demonstrated in clinical research.

Does stem cell therapy replace rehabilitation after stroke?

No. Stem cells appear to work by supporting the brain’s natural repair and plasticity processes — which means rehabilitation is needed to actually drive those processes. Physiotherapy, speech therapy, and occupational therapy remain essential. Stem cell therapy is best understood as a potential adjunct that may extend the recovery window, not a substitute for structured rehabilitation.

How many sessions are needed?

Protocols vary. Some studies have used a single infusion; others have used multiple sessions over several days or weeks. There is no universally agreed standard. A treating physician should be able to explain the rationale for the specific protocol they recommend.

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation LINE: @ednawellness WhatsApp: +66 (0) 64 505 5599 www.ednawellness.com

References

• Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005;57(6):874–882. https://pubmed.ncbi.nlm.nih.gov/15929052/
• Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. https://pmc.ncbi.nlm.nih.gov/articles/PMC3485008/
• Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(5):360–368. https://pubmed.ncbi.nlm.nih.gov/28364993/
• Wang Q, Duan F, Wang MX, et al. Effect of stem cell-based therapy for ischemic stroke treatment: a meta-analysis. Clin Neurol Neurosurg. 2016;146:1–11. https://pubmed.ncbi.nlm.nih.gov/27131124/
• Li Z, Dong X, Tian M, et al. Stem cell-based therapies for ischemic stroke: a systematic review and meta-analysis of clinical trials. Stem Cell Res Ther. 2020;11(1):252. https://pmc.ncbi.nlm.nih.gov/articles/PMC7318436/
• Jiang Y, Zhu W, Zhu J, Wu L, Xu G, Liu X. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of the lesion artery in patients with stroke in the territory of the middle cerebral artery. Cell Transplant. 2013;22(12):2291–2298. https://pubmed.ncbi.nlm.nih.gov/23127560/